These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 30903644)
1. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Kuwano M; Shibata T; Watari K; Ono M Cancer Sci; 2019 May; 110(5):1536-1543. PubMed ID: 30903644 [TBL] [Abstract][Full Text] [Related]
2. Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance. Shibata T; Watari K; Kawahara A; Sudo T; Hattori S; Murakami Y; Izumi H; Itou J; Toi M; Akiba J; Akagi Y; Tanaka M; Kuwano M; Ono M Mol Cancer Ther; 2020 Mar; 19(3):882-894. PubMed ID: 31879363 [TBL] [Abstract][Full Text] [Related]
3. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma. Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615 [TBL] [Abstract][Full Text] [Related]
4. Co-targeting CK2α and YBX1 suppresses tumor progression by coordinated inhibition of the PI3K/AKT signaling pathway. Xu WF; Ma YC; Ma HS; Shi L; Mu H; Ou WB; Peng J; Li TT; Qin T; Zhou HM; Fu XQ; Li XH Cell Cycle; 2019 Dec; 18(24):3472-3490. PubMed ID: 31713447 [TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression. Shibata T; Watari K; Izumi H; Kawahara A; Hattori S; Fukumitsu C; Murakami Y; Takahashi R; Toh U; Ito KI; Ohdo S; Tanaka M; Kage M; Kuwano M; Ono M Cancer Res; 2017 Jan; 77(2):545-556. PubMed ID: 27879270 [TBL] [Abstract][Full Text] [Related]
6. TAGLN2 induces resistance signature ISGs by activating AKT-YBX1 signal with dual pathways and mediates the IFN-related DNA damage resistance in gastric cancer. Zhuo H; Hou J; Hong Z; Yu S; Peng H; Zhang L; Xie W; Hong X Cell Death Dis; 2024 Aug; 15(8):608. PubMed ID: 39168971 [TBL] [Abstract][Full Text] [Related]
7. Interaction network analysis of YBX1 for identification of therapeutic targets in adenocarcinomas. Murugesan SN; Yadav BS; Maurya PK; Chaudhary A; Singh S; Mani A J Biosci; 2019 Jun; 44(2):. PubMed ID: 31180040 [TBL] [Abstract][Full Text] [Related]
8. Novel Serine 176 Phosphorylation of YBX1 Activates NF-κB in Colon Cancer. Martin M; Hua L; Wang B; Wei H; Prabhu L; Hartley AV; Jiang G; Liu Y; Lu T J Biol Chem; 2017 Feb; 292(8):3433-3444. PubMed ID: 28077578 [TBL] [Abstract][Full Text] [Related]
9. A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance. Alkrekshi A; Wang W; Rana PS; Markovic V; Sossey-Alaoui K Cell Signal; 2021 Sep; 85():110073. PubMed ID: 34224843 [TBL] [Abstract][Full Text] [Related]
10. PRMT5-mediated methylation of YBX1 regulates NF-κB activity in colorectal cancer. Hartley AV; Wang B; Mundade R; Jiang G; Sun M; Wei H; Sun S; Liu Y; Lu T Sci Rep; 2020 Sep; 10(1):15934. PubMed ID: 32985589 [TBL] [Abstract][Full Text] [Related]
11. Role of post-translational modification of the Y box binding protein 1 in human cancers. Prabhu L; Hartley AV; Martin M; Warsame F; Sun E; Lu T Genes Dis; 2015 Sep; 2(3):240-246. PubMed ID: 30258867 [TBL] [Abstract][Full Text] [Related]
12. Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y? Dolfini D; Mantovani R Cell Death Differ; 2013 May; 20(5):676-85. PubMed ID: 23449390 [TBL] [Abstract][Full Text] [Related]
13. Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G Murakami Y; Katsuchi D; Matsumoto T; Kanazawa K; Shibata T; Kawahara A; Akiba J; Yanaihara N; Okamoto A; Itamochi H; Sugiyama T; Terada A; Nishio S; Tsuda N; Kato K; Ono M; Kuwano M Sci Rep; 2024 Sep; 14(1):21701. PubMed ID: 39289424 [TBL] [Abstract][Full Text] [Related]
14. Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer. Prabhu L; Mundade R; Wang B; Wei H; Hartley AV; Martin M; McElyea K; Temm CJ; Sandusky G; Liu Y; Lu T Oncotarget; 2015 Oct; 6(30):29396-412. PubMed ID: 26318844 [TBL] [Abstract][Full Text] [Related]
15. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949 [TBL] [Abstract][Full Text] [Related]
16. YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification. Meng H; Miao H; Zhang Y; Chen T; Yuan L; Wan Y; Jiang Y; Zhang L; Cheng W Cancer Lett; 2024 Aug; 597():217064. PubMed ID: 38880223 [TBL] [Abstract][Full Text] [Related]
17. High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma. Zhou LL; Ni J; Feng WT; Yao R; Yue S; Zhu YN; Tang HY; Lv LY; Feng JF; Zhu WG Exp Cell Res; 2017 Dec; 361(1):126-134. PubMed ID: 29024700 [TBL] [Abstract][Full Text] [Related]
18. In silico analysis of overall survival with YBX1 in male and female solid tumours. Grimes DR; Rassamegevanon T; Marignol L Sci Rep; 2024 Mar; 14(1):7218. PubMed ID: 38538658 [TBL] [Abstract][Full Text] [Related]
19. Modulation of YBX1-mediated PANoptosis inhibition by PPM1B and USP10 confers chemoresistance to oxaliplatin in gastric cancer. Lin C; Lin P; Yao H; Liu S; Lin X; He R; Teng Z; Zuo X; Li Y; Ye J; Zhu G Cancer Lett; 2024 Apr; 587():216712. PubMed ID: 38364962 [TBL] [Abstract][Full Text] [Related]
20. Loss of CDH1 up-regulates epidermal growth factor receptor via phosphorylation of YBX1 in non-small cell lung cancer cells. Liu X; Su L; Liu X FEBS Lett; 2013 Dec; 587(24):3995-4000. PubMed ID: 24211838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]